Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Systems and methods for the treatment of plants, including decarboxylation, photo-oxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.

Systems and methods for the treatment of plants, including decarboxylation, photo-oxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.

The present disclosure relates to processes for preparing functionalized cyclooctenes and the synthetic intermediates prepared thereby.

The present disclosure relates to processes for preparing functionalized cyclooctenes and the synthetic intermediates prepared thereby.

Compounds which directly inhibit IRE-1 activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Compounds which directly inhibit IRE-1 activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.